New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT05038839
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-stage trial tested two drugs, cabozantinib and pamiparib, in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the drugs worked together to block cancer cell growth. The study focused on tumors with specific genetic changes, like BRCA mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.